NVIDIA Collaborates With Industry Leaders to Revolutionize Genomics, Drug Discovery, and Healthcare
The healthcare and life sciences industries are undergoing a transformative shift, driven by the convergence of artificial intelligence (AI), accelerated computing, and biological data. NVIDIA, a leader in AI and high-performance computing, has announced groundbreaking partnerships with industry giants like IQVIA, Illumina, Mayo Clinic, and Arc Institute to accelerate innovation in genomics, drug discovery, and advanced healthcare solutions. Together, these collaborations aim to revolutionize the $10 trillion healthcare sector, addressing challenges such as operational inefficiencies, disease detection, and personalized medicine.
AI-Driven Solutions for Drug Discovery and Medical Innovation
IQVIA, a global leader in clinical research services and healthcare intelligence, is leveraging NVIDIA’s AI Foundry service to build custom foundation models tailored to the life sciences industry. With access to over 64 petabytes of healthcare data, IQVIA is developing agentic AI solutions powered by NVIDIA AI Enterprise software, including NIM™ microservices and Blueprints. These tools streamline workflows for research, clinical development, and treatment delivery, ensuring compliance with privacy regulations and patient safety standards.
“This collaboration represents a significant leap forward in applying AI to healthcare and life sciences,” said Bhavik Patel, president of commercial solutions at IQVIA. “By combining our deep domain expertise with NVIDIA’s cutting-edge AI technologies, we’re creating innovative solutions that accelerate drug discovery and bring treatments to market faster.”
These advancements not only enhance efficiency but also unlock an AI factory opportunity worth hundreds of billions of dollars, addressing the $3 trillion spent annually on operational support within the healthcare industry.
Unlocking the Next Era of Genomic Breakthroughs
Illumina, a pioneer in DNA sequencing and informatics, is partnering with NVIDIA to supercharge genomic analysis and multiomics research. By integrating NVIDIA’s accelerated computing and AI toolsets into its DRAGEN analysis software and Illumina Connected Analytics platform, Illumina aims to make genomic insights more accessible to researchers, pharmaceutical companies, and other stakeholders.
The integration of NVIDIA RAPIDS™ for accelerated data science, BioNeMo™ for generative AI modeling, and MONAI for spatial cell imaging workflows will empower scientists to analyze complex datasets with unprecedented speed and accuracy. This collaboration also focuses on developing biology foundation models to drive breakthroughs in target identification, clinical development, and biomarker discovery.
“Our partnership with NVIDIA is revolutionizing how we understand disease through AI and multiomics data,” said Steve Barnard, chief technology officer at Illumina. “Together, we’re enabling pharma and biotech companies to unlock transformative insights and improve success rates in developing lifesaving therapies.”
AI-Powered Digital Pathology: A Game-Changer for Diagnostics
Pathology plays a critical role in diagnosing cancer and other serious conditions, yet it remains a slow and manual process. To address this challenge, Mayo Clinic has developed an AI-powered digital pathology platform featuring autonomous robotic labs and advanced imaging technology. The platform boasts a unique dataset of 20 million whole-slide images linked to 10 million patient records, providing a robust foundation for training next-generation AI models.
Mayo Clinic is deploying NVIDIA DGX™ Blackwell systems—powered by the NVIDIA Blackwell architecture and offering 1.4TB of GPU memory per system—to accelerate the development of pathology foundation models. These models will serve as the cornerstone for future AI applications in drug discovery, personalized diagnostics, and predictive treatment strategies. Additionally, NVIDIA’s MONAI imaging platform and Cosmos Nemotron vision language models will further enhance Mayo Clinic’s ability to deliver personalized healthcare experiences.
“Through our collaboration with NVIDIA, we’re pioneering AI-driven innovations that will transform pathology and improve patient outcomes,” said a representative from Mayo Clinic. “This partnership exemplifies the power of combining clinical expertise with advanced AI technologies.”
Scaling Open Science Biology AI Models With Arc Institute
Arc Institute, a research organization based in Palo Alto, California, is collaborating with NVIDIA to develop and share powerful AI models that advance biomedical discovery. Arc’s team of biology and machine learning researchers is working closely with NVIDIA engineers to scale foundation models capable of generalizing across different biological modalities, including DNA, RNA, and proteins.
This collaboration leverages NVIDIA’s BioNeMo platform, DGX Cloud for optimized model training, and NIM microservices to enable scalable, open-science solutions. By democratizing access to advanced AI tools, Arc Institute and NVIDIA aim to accelerate discoveries in drug discovery, synthetic biology, disease research, and evolutionary studies.
Transforming Healthcare Through AI and Accelerated Computing
The combination of NVIDIA’s AI and accelerated computing capabilities with the expertise of industry leaders is poised to usher in a new era of medical and biological innovation. From speeding clinical trials and enhancing genomic research to advancing digital pathology and personalized medicine, these partnerships are paving the way for improved patient outcomes worldwide.
“AI offers an exceptional opportunity to advance healthcare and life sciences,” said Kimberly Powell, vice president of healthcare at NVIDIA. “By harnessing the power of AI, we can detect diseases earlier, discover new treatments faster, and create more efficient healthcare systems.”
As the healthcare and life sciences industries continue to evolve, NVIDIA’s collaborations with IQVIA, Illumina, Mayo Clinic, and Arc Institute demonstrate the immense potential of AI and accelerated computing to drive meaningful change. These efforts not only address current challenges but also lay the groundwork for a healthier, more innovative future.
About NVIDIA
NVIDIA (NASDAQ: NVDA) is the world leader in accelerated computing.Certain statements in this press release including, but not limited to, statements as to: the benefits, impact, availability, and performance of NVIDIA’s products, services, and technologies, including NVIDIA AI Foundry, NVIDIA NIM microservices, NVIDIA Blueprints, NVIDIA RAPIDS, NVIDIA AI Enterprise software platform, NVIDIA BioNeMo, NVIDIA MONAI, NVIDIA DGX B200 systems, NVIDIA Blackwell architecture, and NVIDIA DGX Cloud; NVIDIA’s partnership and collaboration with third parties, and the benefit and impact thereof; third parties adopting NVIDIA’s products and technologies, the benefits and impact thereof, and the features and performance of their offerings; and the combination of NVIDIA’s AI and accelerated computing capabilities with the expertise of industry leaders being poised to usher in a new era of medical and biological innovation and improve patient outcomes worldwide are forward-looking statements that are subject to risks and uncertainties that could cause results to be materially different than expectations. Important factors that could cause actual results to differ materially include: global economic conditions; our reliance on third parties to manufacture, assemble, package and test our products; the impact of technological development and competition; development of new products and technologies or enhancements to our existing product and technologies; market acceptance of our products or our partners’ products; design, manufacturing or software defects; changes in consumer preferences or demands; changes in industry standards and interfaces; unexpected loss of performance of our products or technologies when integrated into systems; as well as other factors detailed from time to time in the most recent reports NVIDIA files with the Securities and Exchange Commission, or SEC, including, but not limited to, its annual report on Form 10-K and quarterly reports on Form 10-Q. Copies of reports filed with the SEC are posted on the company’s website and are available from NVIDIA without charge. These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, NVIDIA disclaims any obligation to update these forward-looking statements to reflect future events or circumstances.
Many of the products and features described herein remain in various stages and will be offered on a when-and-if-available basis. The statements above are not intended to be, and should not be interpreted as a commitment, promise, or legal obligation, and the development, release, and timing of any features or functionalities described for our products is subject to change and remains at the sole discretion of NVIDIA. NVIDIA will have no liability for failure to deliver or delay in the delivery of any of the products, features or functions set forth herein.
